Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

91 results about "Cell type specific" patented technology

Compositions, methods and uses for treating cystic fibrosis and related disorders

Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled with a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.
Owner:RECODE THERAPEUTICS INC +1

Systems for cell control

ActiveUS12344855B2HydrolasesNervous system cellsMixed cellMixed Cellular Population
The disclosure relates to growing cells, directing cells to grow into specified cell types, genetically and physically manipulating cells, and addressing one or more individual cells within a mixed cell population. Aspects of the disclosure relate to vectors useful to induce developmental changes in cells, in which those vectors have a temporal component. Vectors of the disclosure encode a controllable, temporal series of events. Once the vectors are delivered into target cells, a series of discrete and different genetic events may be induced. The disclosed methods generally provide for the temporal encoding of multiplex genetic effectors in vector format for cell state transitions.
Owner:CELLINO BIOTECH INC

Mutant polypeptide, composition containing mutant polypeptide and application of mutant polypeptide

Provided herein are viral particles comprising a heterologous viral glycoprotein and a targeting moiety wherein the targeting moiety comprises a polypeptide comprising the formula T-S1 wherein T is a target binding domain and Si is a stem moiety. The stem portion may comprise a variant Fc domain. The stem portion may comprise a flexible polypeptide domain. The targeting moiety comprising the formula T-S1 may be incorporated into viral particles to help target such particles to specific cell types. Also provided herein are compositions comprising the viral particles, and methods of use thereof.
Owner:INTERIUS BIOTHERAPEUTICS INC

System and method for target or biomarker identification

PCT designated stage expiredWO2025049446A2TherapiesHealth-index calculationMedicineBiomarker identification
A method for identifying key targets or biomarkers of a disease at a cell specific level according to a two-step process that comprises: (1) identifying cell type-specific candidate targets / biomarkers with genetically defined causal relationships to one or more disease features by performing causal analysis (e.g., 2 sample mendelian randomization); and (2) ranking candidate targets / biomarkers by analyzing the interconnectivity between the identified candidate targets / biomarkers and common interactors / regulators in a customized cell type-specific knowledge graph.
Owner:VALO HEALTH INC

Determining specificity of microcapsules for specific cell types

It is an object of the present invention to provide transport microcapsules that are ingested by a target cell type and permanently or temporarily alter the target cell without thereby causing a toxic effect on the cell. The solution according to the invention consists in the use of a monodisperse core to thereby produce polyelectrolyte nanocapsules having cell-specific dimensions, in which the dimensions for hematopoietic cells range from 20 to 80 nm, preferably from 40 to 60 nm. The size of the particles must be in a very narrow range to prevent the occurrence of toxic effects. In order to maintain the low toxicity of nanomicrocapsules, it is also important to remove nanoparticles (cores) surrounding which create microcapsules prior to use. The method for this purpose is known in the prior art (e.g., using EDTA removal). Another object of the invention is the stabilization of transport microcapsules. The solution according to the invention consists in modifying microcapsules, layers and / or carriers to be packaged by functional groups, allowing stabilization and thus long-term storage at room temperature. The third purpose of the invention is targeted introduction of transport microcapsules. The solution according to the invention is functionalization of the layer by chemical modification and / or supplementation of the layer with antibodies, proteins or peptides.
Owner:CAPCO BIOTECHNOLOGY CO LTD +1

Deaminase-based RNA sensors

RNA editing tools for use in systems designed to measure RNA in vivo and manipulate specific cell types are disclosed herein. An RNA sensor system comprising a) a single-stranded RNA (ssRNA) sensor comprising a stop codon and a payload; optionally wherein the ssRNA sensor further comprises a normalizing gene; and b) an adenosine deaminase acting on RNA (ADAR) deaminase; wherein the sensor is capable of binding to a ssRNA target to form a double-stranded RNA (dsRNA) duplex that becomes a substrate for the ADAR deaminase; wherein the substrate comprises a mispairing within the stop codon; and wherein the mispairing is editable by the ADAR deaminase, which editing can effectively remove the stop codon so as to enable translation and expression of the payload. A method of quantifying ribonucleic acid (RNA) levels using the RNA sensor system is also disclosed.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Regulatory element for cell type specific expression of genes in spinal motor neurons

PendingUS20250135029A1Organic active ingredientsVectorsCholinergic cellsPrimary motor neuron
The subject matter described here relates to an enhancer specific to a subset of cholinergic neurons, that can control gene expression in a highly neuron-specific manner, wherein the enhancer is compatible with AAVs packaging and can induce gene expression or knockdown in cholinergic neurons in both post-natal and adult subjects.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK

Viral vectors and producing cells

Provided is a viral vector having a lipid bilayer envelope, the lipid bilayer envelope comprising an antibody binding domain displayed outside the envelope, the antibody binding domain being cell type specific; a viral envelope protein exhibited outside the envelope, the viral envelope protein being capable of promoting infection of the same cell type; and a nucleic acid molecule comprising a promoter capable of being expressed in the same cell type. Methods of making the viral vectors and methods of modifying cells and treating diseases / conditions using the viral vectors are also provided.
Owner:AESOP BIOTECHNOLOGY CO LTD

Molecular guide system peptides and uses thereof

To provide compositions and methods for delivering therapeutic antibodies to a specific cell type and to specific locations within that cell.SOLUTION: Disclosed are compositions comprising an antibody conjugated to one or more molecular guidance system (MGS) peptides. Disclosed are methods of treating a subject in need thereof comprising administering to the subject in need thereof an effective amount of an antibody conjugated to one or more MGS peptides, wherein the antibody targets an intracellular target involved in the disease process. Disclosed are methods of targeting an intracellular target, comprising administering an antibody conjugated to one or more MGS peptides, wherein the antibody targets an intracellular target.SELECTED DRAWING: None
Owner:SRI INTERNATIONAL

Device and method for microdroplet detection of cells

A method for using a device for manipulating and / or determining one or more characteristics of cells or micro-bead contained within a biological sample is provided. The device comprises: a sorting component configured to separate cell-containing or micro-bead containing microdroplets from empty ones into a population of cell-containing or micro-bead containing first microdroplets; a microdroplet manipulation component configured to manipulate the first microdroplets in a first zone configured to arrange the first microdroplets into an array for optical inspection and a second zone located within or adjacent the first zone and configured to detect merged microdroplets in one or more detection windows; and an optical detection system configured to detect an optical signal from the microdroplets via the one or more detection windows and to analyse the contents of each microdroplet to determine one or more characteristics of a cell or micro-bead contained in that microdroplet. The method comprises the steps of: creating from the biological sample aqueous first microdroplets in an immiscible carrier fluid, at least some of which are believed to contain cells of a particular cell type; moving the first microdroplets along a pathway using real or virtual electrodes to at least one microdroplet-merging location; merging reporter system containing microdroplets into the first microdroplets to produce merged microdroplets; analyzing the contents of each merged microdroplet with an optical detection system and detecting an optical signal characteristic of an interaction between the cell or micro-bead and the reporter system.
Owner:LIGHTCAST DISCOVERY LTD

Method for constructing neurodevelopmental disorder animal model based on central nervous system myelin sheath function change and application

PendingCN121271960ATransferasesFermentationKnockout animalDevelopmental disorder
The invention discloses a method for constructing a neurodevelopmental disorder animal model based on central nervous system myelin sheath function change and application, and belongs to the technical field of biological engineering. An Msl2 gene conditional knockout mouse model is constructed by adopting a gene engineering technology, the space-time specific knockout of a second exon of the Msl2 gene in a specific cell type is realized through a Cre-LoxP recombinase system, and the exon encodes a key enzyme activity region for catalyzing ubiquitination. Model construction is based on central nervous system oligodendrocyte / myelin sheath dysfunction, the behavior phenotype of the model is similar to the behavior of a typical neurodevelopment disorder animal, a brand new perspective is provided for exploring an etiology mechanism, model mice can be prepared on a large scale by performing directional mating on the gene modified mice, and the development of the model is promoted. And consistency of different experiment batches and reliable reproduction of experiment data are ensured.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

Protein nanospheres and method to treat dysfunction from chemotherapy and immunosuppressive therapy

A protein nanospheres and method to treat dysfunction from chemotherapy and immunosuppressive therapy, and a manufacture of fibrinogen-coated albumin spheres (FAS) and High-Fibrinogen Spheres (HFS) which have higher concentrations of fibrinogen molecules per sphere than FAS, and their use for medical treatments. Both kinds of nanoparticles are effective in the mitigation of the toxic effects of certain chemotherapeutic and radiological agents that are typically used in the treatment of cancer, or the treatment of autoimmune diseases, or for patients with both diseases. FAS and HFS can exert their beneficial effects via a variety of mechanisms which match the need of the body for specific cell types, including any of the subgroups of T cells and antibody producing cells, the relative concentration of each kind is vital to the balance between tumor surveillance and autoimmune disease suppression.
Owner:YEN RICHARD C K

PSMA-targeting linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same

The present invention relates to polyplexes comprising linear conjugates of LPEI and PEG. The LPEI and PEG fragments of the linear conjugates are preferably linked by a [3+2]cycloaddition between an azide and an alkene or an alkyne to produce a 1, 2, 3 triazole or a 4,5-dihydro-1H-[1,2,3]triazole. The linear conjugates are further conjugated to a targeting fragment capable of binding to prostate specific membrane antigen (PSMA) to enable selective interaction with a particular cell type. The conjugates can form polyplexes with therapeutic agents such as nucleic acids to deliver the therapeutic agents to cells.
Owner:TARGIMMUNE THERAPEUTICS AG

Radiolabeled biomolecules and use thereof

To provide radiolabeled biomolecules and methods for radiolabeling biomolecules with radioactive halogen atoms, where the methods minimize loss of the radioactive halogen due to dehalogenation in vivo, preserve the biological activity of the biomolecules, maximize retention of radioactivity in cancer cells, and minimize retention of radioactivity in normal tissues after in vivo administration.SOLUTION: Some of such radiolabeled biomolecules comprise a radioactive metal atom in place of or in addition to the radioactive halogen. The biomolecules have affinity for particular types of cells and may specifically bind to certain cells, such as cancer cells. Relevant biomolecules include antibodies, monoclonal antibodies, antibody fragments, peptides, other proteins, nanoparticles and aptamers.SELECTED DRAWING: None
Owner:DUKE UNIV

Methods to genetically modify cells for delivery of therapeutic proteins

The present disclosure provides methods to genetically modify cells by insertion of an artificial exon (ArtEx) for delivery of therapeutic proteins in specific cell types and more particularly engineered cells for expression of a transgene into the brain of a patient.
Owner:CELLECTIS SA

Fragmentomics in cerebrospinal fluid

Various embodiments are directed to the analysis of fragmentation patterns of cell-free DNA (cfDNA) circulating in cerebrospinal fluid (CSF) and the potential applications. CSF is an important liquid biopsy sample used to study the central nervous system and related disorders, such as infection and malignancies. The characterization of fragmentation patterns of cfDNA in CSF includes the size profile, end motif, cleavage profiles, and the determination of epigenetic features, including methylation. Various applications can use one or more properties of fragmentation pattern, for example, in the determination of the proportional contribution of a particular cell types in the CSF cfDNA pool. Another purpose is the diagnosis of pathology in the central nervous system, by the detection of clinically relevant DNA (e.g., tumor fraction, pathogen). DNA fragments in CSF can be analyzed in various ways, including using short-read sequencing, and / or long-read sequencer technologies.
Owner:CENT FOR NOVOSTICS

Multimodal silica-based nanoparticles

The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeutic agent may be attached to the nanoparticle. To permit the nanoparticle to be detectable by not only optical fluorescence imaging, but also other imaging techniques, such as positron emission tomography (PET), single photon emission computed tomography (SPECT), computerized tomography (CT), bioluminescence imaging, and magnetic resonance imaging (MRI), radionuclides / radiometals or paramagnetic ions may be conjugated to the nanoparticle.
Owner:SLOAN KETTERING INST FOR CANCER RES +1

Hepatocyte targeting molecules and methods of use thereof

Provided for herein are viral particles comprising a heterologous viral glycoprotein and a targeting moiety, wherein the targeting moiety comprises a polypeptide comprising a formula of T-S1, wherein T is a target binding domain that targets the viral particle to the liver and S1 is a stalk portion. The stalk portion may comprise a variant Fc domain. The stalk portion may comprise a flexible polypeptide domain. The targeting moiety comprising the formula T-S1 may be incorporated into a viral particle to assist with targeting such particles to a specific cell type. Also provided for herein are compositions comprising the same, and methods of using the same.
Owner:INTERIUS BIOTHERAPEUTICS INC

Cell type specific enhancers, methods and uses related thereto

PCT designated stage expiredWO2025122559A1VectorsFermentationDiseaseCell type specific
Provided are isolated, cloned enhancer element sequences that target certain neuronal cell types, subtypes, and / or populations in the brain and CNS. The isolated and cloned enhancer elements can target a gene of interest, such as a therapeutic gene or an effector gene, to be expressed in the certain cell types. Virus vectors containing the isolated, cloned enhancer element sequences, particularly, recombinant adeno-associated virus (rAAV) vectors, and a gene or polynucleotide to be expressed in a given neuronal cell type are described. The rAAV vectors, compositions and methods are useful for treating subjects afflicted with neuropsychiatric and neuropathological diseases, disorders and conditions and symptoms thereof.
Owner:THE BROAD INST INC +1

Multi-specific reagent for targeted delivery of lipid nanoparticles

PCT designated stage expiredWO2025006406A1ApolipeptidesHybrid immunoglobulinsT cellCell type specific
The present disclosure relates to a molecular delivery system that facilitates the internalization of LNPs into a specific target of choice, such as a specific cell type, ex vivo and / or in vivo. The present disclosure also relates to methods, molecules, and compositions for enhancing the targeted delivery of compounds within a living system. In particular, embodiments provided herein relate to methods, molecules, and compositions for the targeted delivery of lipid nanoparticles containing therapeutic molecules into a cell or system of choice, such as a T cell. The present disclosure also relates to methods of administering the enhanced targeting system to a patient or system, compositions for use in such methods, and further methods of use of the targeting system as part of T cell-based immunotherapy.
Owner:CHIMERIS UK LTD +1

Imparting unique cell-scaffold interactions to create self-organizing tissues

The present disclosure is directed to scaffold materials patterned with cell adhesion targets that permit the attachment and growth of predetermined cell types onto the scaffold. By selecting specific ligands that are patterned on the scaffold, particular cell types, including those engineered for this specific purpose, will attach and proliferate to create designed tissues and organs.
Owner:WILLIAM MARCH RICE UNIVERSITY

Crosslinked polymer nanoparticles for targeted cellular uptake and therapeutics, and compositions and methods thereof

The invention provides novel compounds, pharmaceutical compositions and methods of preparation and therapeutic use thereof. The invention also provides novel gel compositions comprising hyaluronic acid (HA) polymers that are crosslinked with appropriate reversible crosslinkers and encapsulation of therapeutics or other payloads in such gel composition and nanoparticles thereof. The invention also relates to targeted delivery of such gel compositions and nanoparticles to specific cell types in a controllable delivery and release. The invention additionally relates to methods of therapeutic use of such gel compositions and nanoparticles in treatment of various diseases and conditions. The invention further relates to methods of preparation of the gel compositions and nanoparticles disclosed herein.
Owner:UNIV OF MASSACHUSETTS

Targeting linear conjugates comprising polyethyleneimine and polyethylene glycol and polymer composites comprising same

The present invention relates to polymer complexes comprising linear conjugates of LPEI and PEG. The LPEI fragment and the PEG fragment of the linear conjugate are preferably connected through [3 + 2] cycloaddition reaction between azide and olefin or alkyne to generate 1, 2, 3 triazole or 4, 5-dihydro-1H-[1, 2, 3] triazole. The linear conjugates are preferably further conjugated to targeting fragments to achieve selective interaction with specific cell types. The conjugate may form a polymer complex with a therapeutic agent (e.g., a nucleic acid) to deliver the therapeutic agent to a cell.
Owner:TARGIMMUNE THERAPEUTICS AG

Device and method for microdroplet detection of cells

A method for using a device for manipulating and / or determining one or more characteristics of cells or micro-bead contained within a biological sample is provided. The device comprises: a sorting component configured to separate cell-containing or micro-bead containing microdroplets from empty ones into a population of cell-containing or micro-bead containing first microdroplets; a microdroplet manipulation component configured to manipulate the first microdroplets in a first zone configured to arrange the first microdroplets into an array for optical inspection and a second zone located within or adjacent the first zone and configured to detect merged microdroplets in one or more detection windows; and an optical detection system configured to detect an optical signal from the microdroplets via the one or more detection windows and to analyse the contents of each microdroplet to determine one or more characteristics of a cell or micro-bead contained in that microdroplet. The method comprises the steps of: creating from the biological sample aqueous first microdroplets in an immiscible carrier fluid, at least some of which are believed to contain cells of a particular cell type; moving the first microdroplets along a pathway using real or virtual electrodes to at least one microdroplet-merging location; merging reporter system containing microdroplets into the first microdroplets to produce merged microdroplets; analyzing the contents of each merged microdroplet with an optical detection system and detecting an optical signal characteristic of an interaction between the cell or micro-bead and the reporter system.
Owner:LIGHTCAST DISCOVERY LTD

PSMA-targeted linear conjugates containing polyethyleneimine and polyethylene glycol and polyplexes containing the same

The present invention relates to a polyplex comprising a linear conjugate of LPEI and PEG. The LPEI and PEG fragments of the linear conjugate are preferably linked by a [3+2] cycloaddition between azide and alkene or alkyne to generate 1,2,3 triazole or 4,5-dihydro-1H-[1,2,3]triazole. The linear conjugate is further conjugated to a targeting fragment that can bind to prostate-specific membrane antigen (PSMA) to enable selective interaction with specific cell types. The conjugate can form a polyplex with a therapeutic agent, such as a nucleic acid, to deliver the therapeutic agent to cells.
Owner:TARGIMMUNE THERAPEUTICS AG

Systems for cell control

PendingUS20250283108A1HydrolasesNervous system cellsMixed cellMixed Cellular Population
The disclosure relates to growing cells, directing cells to grow into specified cell types, genetically and physically manipulating cells, and addressing one or more individual cells within a mixed cell population. Aspects of the disclosure relate to vectors useful to induce developmental changes in cells, in which those vectors have a temporal component. Vectors of the disclosure encode a controllable, temporal series of events. Once the vectors are delivered into target cells, a series of discrete and different genetic events may be induced. The disclosed methods generally provide for the temporal encoding of multiplex genetic effectors in vector format for cell state transitions.
Owner:CELLINO BIOTECH INC

Polyplexes of nucleic acids with targeted conjugates containing polyethyleneimine and polyethylene glycol

The present invention provides a targeting polyplex composed of (i) a nucleic acid, particularly a nucleic acid encoding a pharmaceutically active peptide or protein, and (ii) a targeting conjugate comprising an LPEI and a PEG fragment connected by distinct linkages formed by a defined chemoselective reaction. Thus, the LPEI fragment is linked to a single PEG fragment in a linear, end-to-end manner. The linear conjugate is further conjugated to a targeting fragment to enable selective interaction with specific cell types. The polyplex selectively delivers the nucleic acid to target cells, resulting in high expression and efficient protein translation and secretion of the encoded pharmaceutically active protein.
Owner:TARGIMMUNE THERAPEUTICS AG

Drug screening analysis methods, media and equipment based on single-cell transcriptome profiles

The present application discloses a drug screening analysis method, medium and equipment based on single-cell transcriptome maps, which relates to the field of single-cell transcriptome data analysis. Constructing a single-cell pan-tumor transcriptome map containing cancer tissues of various cancer types, corresponding paracancerous tissues and corresponding tissues from normal human bodies is helpful to discover common drug targets across different cancer types; through re-clustering and annotation, it is possible to accurately distinguish different cell types, especially the differences between malignant cells and normal cells, which is helpful to discover drugs for specific cell types; based on the single-cell pan-tumor transcriptome map, combined with the pre-processed cell perturbation data matrix, the deep learning model is trained to achieve accurate prediction of cell response under drug treatment, which can quickly identify pan-tumor drugs and tumor-specific drugs, discover new indications for marketed drugs and candidate drugs, evaluate the side effects of drugs, and discover the potential mechanism of action of drugs.
Owner:ZHEJIANG UNIV

Polymer complexes of targeting conjugates comprising polyethyleneimine and polyethylene glycol and nucleic acids

The present invention provides targeted polymer complexes comprising: (i) a nucleic acid, in particular a nucleic acid encoding a peptide or protein having pharmaceutical activity; and (ii) a targeting conjugate comprising LPEI and PEG fragments linked by discrete bonds formed by a defined chemically selective reaction. Thus, the LPEI fragment is bonded to a single PEG fragment in a linear end-to-end manner. The linear conjugate is further conjugated to a targeting fragment to achieve selective interaction with a particular cell type. The polymer complexes selectively deliver nucleic acids to target cells, thereby achieving high expression and efficient protein translation and secretion of the encoded pharmaceutically active proteins.
Owner:TARGIMMUNE THERAPEUTICS AG